2 research outputs found

    Discovery of Novel Urea-Based Hepatitis C Protease Inhibitors with High Potency against Protease-Inhibitor-Resistant Mutants

    No full text
    The macrocyclic urea <b>2</b>, a byproduct in the synthesis of benzoxaborole <b>1</b>, was identified to be a novel and potent HCV protease inhibitor. We further explored this motif by synthesizing additional urea-based inhibitors and by characterizing them in replicase HCV protease-resistant mutants assay. Several compounds, exemplified by <b>12</b>, were found to be more potent in HCV replicon assays than leading second generation inhibitors such as danoprevir and TMC-435350. Additionally, following oral administration, inhibitor <b>12</b> was found in rat liver in significantly higher concentrations than those reported for both danoprevir and TMC-435350, suggesting that inhibitor <b>12</b> has the combination of anti-HCV and pharmacokinetic properties that warrants further development of this series
    corecore